Did You Know...
...that the video game, Pong, was invented by a guy who graduated at the bottom of his engineering class? Nolan Bushnell spent more time running the games at a local amusement park than he did on his studies at the University of Utah. His dreams of working for Disney's amusement empire were dashed when the company wouldn't hire him. Taking a boring job, Nolan daydreamed about electronic versions of popular games. He invented Pong, the first video game, and went on to found Atari Co.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8133862 | Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having insulin-like growth factor-1 deficiency (IGFD). The invention relates to methods comprising admini... | 03/13/2012 |
| 8067362 | Insulin derivatives The present invention relates to insulin derivatives having a side chain attached either to the -amino group of the N-terminal amino acid residue of the B chain or to the amino group of a Lys residue present in the B chain of the parent insulin via an amide bond whi... | 11/29/2011 |
| 8048854 | Amidated insulin glargine The invention relates to insulin glargine which is modified by amidation, especially Gly(A21), Arg(B31), Arg amide (B32) human insulin (insulin glargine amide). ... | 11/01/2011 |
| 8039434 | Method for producing human insulin-like growth factor I A method is provided for producing hIGF-I with high purity and yield. This is a method for producing human insulin-like growth factor I, having a step of removing modified human insulin-like growth factor I from the human insulin-like growth factor I, the step inclu... | 10/18/2011 |
| 8039431 | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to tha... | 10/18/2011 |
| 7977454 | Preparation of insulin conjugates The present invention discloses a process for making an insulin-oligomer conjugate as a one-pot reaction by conjugation of insulin-ester with an activated oligomer wherein simultaneous deblocking and conjugation is carried out. ... | 07/12/2011 |
| 7872095 | Insulin-oligomer conjugates, formulations and uses thereof An insulin compound coupled to a modifying moiety having a formula: —X—R1—Y-PAG-Z—R (Formula VI) where, X, Y and Z are independently selected linking groups and each is optionally ... | 01/18/2011 |
| 7829664 | Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof An isolated chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1 is provided. Also provided is an isolated modified chimeri... | 11/09/2010 |
| 7795384 | Fusion protein suitable for high efficiency expression and the production method thereof The present invention provides a novel fusion protein suitable for high expression and the production method thereof. The structure of the fusion protein is A-C1-K-(B-C2-K)n-D, wherein A is the upstream peptide; each of C1 and C2 is independently short peptides havi... | 09/14/2010 |
| 7659363 | Process for the preparation of insulin or an insulin derivative in the presence of oxygen The present invention comprises a process for preparing insulin or an insulin derivative with correctly linked cysteine bridges from a precursor of said insulin or insulin derivative, wherein said precursor is subjected to a folding process in the presence of cystei... | 02/09/2010 |
| 7625996 | Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol) The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-... | 12/01/2009 |
| 7442682 | Transepithelial delivery of peptides with incretin hormone activities Compositions and methods are disclosed for the treatment of diabetes and related diseases using peptides with incretin hormone activity. Preferably, the peptide with incretin hormone activity is GLP-1, exendin or an analog of GLP-1 or exendin. The peptides with incr... | 10/28/2008 |
| 7433788 | Crystallization of IGF-1 Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, opti... | 10/07/2008 |
| 7425430 | Probe for visualizing phosphorylation/dephosphorylation of protein and method of detecting and quantifying phosphorylation/dephosphorylation of protein As a versatile method of detecting and assaying intracellular protein phosphorylation and dephosphorylation that enables nondestructive monitoring as well as spatial and temporal analysis for living cells, animal bodies, plant bodies and the like, a probe for imagin... | 09/16/2008 |
| 7407932 | Methods for glucagon suppression using modified exendins Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a ... | 08/05/2008 |
| 7405279 | Chimeric proteins for diagnosis and treatment of diabetes Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins... | 07/29/2008 |
| 7402565 | Processes for making acylated insulin A method is provided which allows high yields of acylated insulin. The method comprises expressing a singe-chain insulin precursor, preferably in yeast, cleaving the single-chain insulin precursor with a suitable protease which will open the peptide bond between the... | 07/22/2008 |
| 7399745 | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders. ... | 07/15/2008 |
| 7396903 | Process for preparing insulin compounds A preferred way of converting insulin precursors into insulin compounds is to perform an enzymatic peptide cleavage in an aqueous medium and, thereafter, without removal of the intermediate product formed, to add an amino acid ester or a peptide ester and an organic... | 07/08/2008 |
| 7384914 | Night-time oral insulin therapy A method for protection of a mammal that has impaired glucose tolerance or early stage diabetes mellitus from developing overt or insulin dependent diabetes comprises administering an orally effective dose of a pharmaceutical formulation comprising insulin at nightt... | 06/10/2008 |
| 7384915 | Chimeric insulin-gad proteins for treating patients with type 1 diabetes or at risk of developing type 1 diabetes Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins... | 06/10/2008 |
| 7383084 | Transdermal delivery system for dried particulate or lyophilized medications The present invention provides a system for transdermal delivery of dried or lyophilized pharmaceutical compositions and methods using thereof. The system comprises an apparatus for facilitating transdermal delivery of an agent that generates hydrophilic micro-chann... | 06/03/2008 |
| 7381702 | Methods of treating diabetes mellitus Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin drug to the patient in order to treat diabetes mellitus in the patient. Methods according to the present invention may “activate”... | 06/03/2008 |
| 7378390 | Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast Novel insulin precursors and insulin precursor analogs comprising a connecting peptide (mini C-peptide) of preferably up to 15 amino acid residues and comprising at least one Gly are provided. The precursors can be converted into human insulin or a human insulin ana... | 05/27/2008 |
| 7371813 | Method for use of IGF-binding protein for selective sensitization of target cells in vivo New methods for the treatment of human disease are provided. IGFBP-3 is administered together with a co-administered agent to subjects having disease, thereby alleviating the symptoms of the disease, under conditions where administration of IGFBP-3 alone at the maxi... | 05/13/2008 |
| 7368260 | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same Methods for synthesizing proinsulin polypeptides are described that include a contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an ol... | 05/06/2008 |
| 7363075 | Transdermal delivery system for dried particulate or lyophilized medications The present invention provides a system for transdermal delivery of dried or lyophilized pharmaceutical compositions and methods using thereof. The system comprises an apparatus for facilitating transdermal delivery of an agent that generates hydrophilic micro-chann... | 04/22/2008 |
| 7354769 | Crystallization of IGF-1 Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, opti... | 04/08/2008 |
| 7354994 | Recombinant IGF expression systems The present invention provides nucleic acid sequences, expression systems, host cells, polypeptides and methods of producing mature insulin-like growth factor (IGF) using a fusion construct which yields high levels of fusion proteins that are easily processed to pro... | 04/08/2008 |
| 7335377 | Transdermal delivery system for dried particulate or lyophilized medications The present invention provides a system for transdermal delivery of dried or lyophilized pharmaceutical compositions and methods using thereof. The system comprises an apparatus for facilitating transdermal delivery of an agent that generates hydrophilic micro-chann... | 02/26/2008 |
| 7335639 | IGF-1 composition and its use A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density of about 1.0 g/ml to... | 02/26/2008 |
| 7323543 | Multiple agent diabetes therapy A pharmaceutical composition includes at least two of agents I)-iii), wherein agent i) is selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin ana... | 01/29/2008 |
| 7316999 | Glucose dependent release of insulin from glucose sensing insulin derivatives Insulin derivatives having a built-in glucose sensor, capable of delivering insulin from a depot as a function of the glucose concentration in the surrounding medium (e.g. tissue), such that the rate of insulin release from the depot increases with an increased gluc... | 01/08/2008 |
| 7317000 | Glucose-dependent insulins The present invention relates to insulin derivatives having a built-in glucose sensor and a polyol moiety, capable to deliver insulin from an injected depot of an insulin derivative according to the invention as a function of the glucose concentration in the surroun... | 01/08/2008 |
| 7314911 | Prostate hyperplasia therapy The invention is a method for treating prostate hyperplasia by contacting a patient with insulin-6 in an amount effective to prevent or reduce prostate hyperplasia. The invention includes transgenic insulin-6 knockout mice that exhibit prostate hyperplasia and that ... | 01/01/2008 |
| 7312192 | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same Methods for synthesizing proinsulin polypeptides are described that include contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an olig... | 12/25/2007 |
| 7309759 | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics Compositions and methods for treating infections, especially bacterial infections, are provided. Indolicidin peptide analogues containing at least two basic amino acids are prepared. The analogues are administered as modified peptides, preferably containing photo-ox... | 12/18/2007 |
| 7297761 | Pharmaceutical compositions containing exendins Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that aff... | 11/20/2007 |
| 7291591 | Alcohol-free transdermal insulin composition The instant invention is directed toward a dermal delivery system composition comprising an aqueous base vehicle including Emu oil, at least one fatty acid alkyl ester, polyethylene glycol, and a gelling agent, in combination with a therapeutically effective amount ... | 11/06/2007 |
| 7288516 | Null IGF for the treatment of cancer New methods for the treatment of cancer are provided. Null IGF (IGF variants with reduced receptor binding) is administered to subjects having cancer, thereby alleviating the symptoms of the cancer. ... | 10/30/2007 |
